KFKari D. Foss

Kari D. Foss

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kari D. Foss has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Likely radiation-induced sciatic neuropathy in a dog

    by Erica Fox, Cassandra Rodenbaugh, Erin Epperly, Inma Ferrandis, G Diane Shelton, Laura Garrett, Kari Foss

    Radiation-induced peripheral neuropathy (RIPN) is a well-known late adverse effect of radiotherapy (RT) in humans, but to date, is not reported in companion animals. An 11-year-old spayed female beagle was presented for evaluation regarding a progressive left sciatic neuropathy. The dog had received stereotactic RT (20 Gy) following excision of a grade 2 soft tissue sarcoma over the proximo-caudal aspect of the left thigh approximately 19 months prior to the onset of signs. Computed tomography and magnetic resonance imaging of the left sciatic nerve was consistent with RIPN, and histopathology of the sciatic nerve supported severe nerve fiber loss. No improvement was observed with an anti-inflammatory course of corticosteroids, and the affected limb was subsequently amputated.

  • Open Access

    Single‐Dose Pharmacokinetics of Intranasal Levetiracetam in Healthy Dogs

    by Jessica L. Wagner, Kari D. Foss, Jennifer M. Reinhart, Lauren E. Forsythe

    Cluster seizures and status epilepticus in dogs are emergencies requiring rapid intervention. Intranasal (IN) benzodiazepines are effective for early seizure cessation, but the pharmacokinetics of longer‐acting antiseizure medications administered IN have not been investigated in dogs. This study aimed to describe the single‐dose pharmacokinetics of a compounded IN levetiracetam product (IN‐LEV) in healthy dogs. We hypothesized that the administration of IN‐LEV to healthy dogs will demonstrate similar pharmacokinetic parameters to IV administration. In a randomized crossover design, nine healthy dogs received a single 30 mg/kg IV dose (100 mg/mL) or a single 30 mg/kg IN dose (460 mg/mL) of levetiracetam. Serum levetiracetam concentrations were serially measured over 24 h. Pharmacokinetic analysis was performed using non‐compartmental methods and comparisons between routes of administration were made using the Wilcoxon signed‐rank test. C max , T max , and t 1/2 for IN‐LEV were 14.6 ± 5.4 μg/mL, 2.3 ± 1.5 h, and 3.6 ± 0.4 h, respectively. IN‐LEV achieved minimum target concentrations (5 μg/mL) within 0.34 ± 0.22 h and maintained these levels for 6.57 ± 3.17 h. Bioavailability for IN‐LEV was 70% ± 27.4%. This study demonstrates that IN levetiracetam rapidly achieves the lowest reference interval concentration, but the high end of the interval was not achieved in any dog with a single 30 mg/kg dose. IN‐LEV may be a viable alternative for emergent seizure management when IV access is unavailable, but multiple doses may be required to achieve seizure cessation in some patients.


  • Open Access

    The Single‐Dose Pharmacokinetics of a Compounded Levetiracetam Formulation and Bioequivalence to a Commercial Formulation in Healthy Dogs

    by Aaron M. Paushter, Kari D. Foss, Jennifer M. Reinhart, Lauren E. Forsythe, Devon W. Hague

    Levetiracetam (LEV) is an anti‐epileptic drug used extra‐label in dogs. Commercially available extended‐release formulations (LEV‐ER), administered twice daily, cannot be crushed or split, limiting their use in small dogs. A compounded LEV‐ER formulation (PO‐COMP) can purportedly be partitioned without loss of extended‐release properties. The aims of this study were to establish the pharmacokinetic parameters of PO‐COMP, divided at the tablet score, and determine the bioequivalence of partitioned PO‐COMP to an intact commercially available Food and Drug Administration‐approved human oral generic formulation of LEV‐ER (PO‐COMM). In a randomized crossover design, 12 healthy dogs received a single IV dose (30 mg/kg) of IV‐COMM, a single oral dose (500 mg) of intact PO‐COMM, or a single oral dose (500 mg) of partitioned PO‐COMP and underwent serial measurement of plasma LEV concentrations over 24 h. PO‐COMP was bioequivalent to PO‐COMM using the 90% confidence interval method for maximum concentration (−3.2% difference [CI −7.4% to −1.1%]) and area under the curve (−14.4% difference [CI −17.8% to 10.8%]). PO‐COMP may improve medication adherence and seizure control relative to immediate‐release LEV, which requires three times daily dosing. Efficacy studies of PO‐COMP are warranted.

  • Open Access

    Magnetic resonance imaging in canine idiopathic epilepsy: a mini-review

    by Kari D. Foss, Audrey C. Billhymer

    Magnetic resonance imaging (MRI) in an integral part of the diagnostic workup in canines with idiopathic epilepsy (IE). While highly sensitive and specific in identifying structural lesions, conventional MRI is unable to detect changes at the microscopic level. Utilizing more advanced neuroimaging techniques may provide further information on changes at the neuronal level in the brain of canines with IE, thus providing crucial information on the pathogenesis of canine epilepsy. Additionally, earlier detection of these changes may aid clinicians in the development of improved and targeted therapies. Advances in MRI techniques are being developed which can assess metabolic, cellular, architectural, and functional alterations; as well alterations in neuronal tissue mechanical properties, some of which are currently being applied in research on canine IE. This mini-review focuses on novel MRI techniques being utilized to better understand canine epilepsy, which include magnetic resonance spectroscopy, diffusion-weighted imaging, diffusion tensor imaging, perfusion-weighted imaging, voxel based morphometry, and functional MRI; as well as techniques applied in human medicine and their potential use in veterinary species.


  • An avian Modified Glasgow Coma Scale as a prognostic indicator in raptors with head trauma

    by Kari D. Foss, Krista A. Keller, Sarah K. Reich, Dana Franzen-Klein, David Scott, Mariana Sosa-Higareda, Devon W. Hague, Julia Whittington, Matthew C. Allender

    OBJECTIVE: To develop a Modified Glasgow Coma Scale (MGCS) for use in raptors presenting with head trauma and assess the agreement of the MGCS scores between examiners with varying backgrounds, and to assess the prognostic value of the avian MGCS in raptors with head trauma. ANIMALS: 156 native raptorial species. METHODS: All raptors received an MGCS assessment within 8 hours of their presentation, between January 1, 2018, and December 31, 2019. For the first objective, the assessment was performed by a veterinary student, a wildlife veterinarian, and a board-certified or resident veterinary neurologist. Each animal received a score in 3 categories (motor activity, level of consciousness, and brain stem reflexes) and an overall score. For the second objective, the MGCS scoring was performed by the intaking clinical team member and survival after 48 hours was documented. RESULTS: Agreement between the 3 individual scores was assessed via Cronbach α and intraclass correlation. There was excellent-good agreement in all 3 assessment categories as well as the overall score. Univariate associations between survival and demographic factors were determined using the χ2 test. Overall, raptors with a total MGCS of < 10 were less likely to survive than those with a score > 12. CLINICAL RELEVANCE: An avian-specific MGCS demonstrated good-excellent agreement among raters of various backgrounds in assessing raptors with head trauma. Additionally, this study showed that an avian-specific MGCS may be correlated with the probability of survival within the first 48 hours after presentation to rehabilitation facilities in raptors with head trauma.


  • Open Access

    Ex vivo comparison of pin placement with patient‐specific drill guides or freehand technique in canine cadaveric spines

    by Francisco Guevara, Kari D. Foss, Tisha A. M. Harper, Clara A. Moran, Devon W. Hague, Philip E. S. Hamel, David J. Schaeffer, Annette M. McCoy

    Objective: To compare vertebral implant placement in the canine thoracolumbar spine between 3D‐printed patient‐specific drill guides (3DPG) and the conventional freehand technique (FH).Study design: Ex vivo study.Animals: Cadaveric canine spines (n = 24).Methods: Implant trajectories were established for the left and right sides of the T10 through L6 vertebrae based on computed tomography (CT) imaging. Customized drill guides were created for each vertebra of interest. Each cadaver was randomly assigned to one of six veterinarians with varying levels of experience placing vertebral implants. Vertebrae were randomly assigned a surgical order and technique (3DPG or FH) for both sides. Postoperative CT images were acquired. A single, blinded observer assessed pin placement using a modified Zdichavsky classification.Results: A total of 480 implants were placed in 240 vertebrae. Three sites were excluded from the analysis; therefore, a total of 238 implants were evaluated using the FH technique and 239 implants using 3DPG. When evaluating implant placement, 152/239 (63.6%) of 3DPG implants were considered to have an acceptable placement in comparison with 115/248 (48.32%) with FH. Overall, pin placement using 3DPG was more likely to provide acceptable pin placement (p < .001) in comparison with the FH technique for surgeons at all levels of experience.Conclusion: The use of 3DPG was shown to be better than the conventional freehand technique regarding acceptable placement of implants in the thoracolumbar spine of canine cadavers.Clinical significance: Utilizing 3DPG can be considered better than the traditional FH technique when placing implants in the canine thoracolumbar spine.


  • Open Access

    A smart coating with integrated physical antimicrobial and strain-mapping functionalities for orthopedic implants

    by Yi Zhang, Jinsong Cui, Kuan-Yu Chen, Shanny Hsuan Kuo, Jaishree Sharma, Rimsha Bhatta, Zheng Liu, Austin Ellis-Mohr, Fufei An, Jiahui Li, et al.

    The prevalence of orthopedic implants is increasing with an aging population. These patients are vulnerable to risks from periprosthetic infections and instrument failures. Here, we present a dual-functional smart polymer foil coating compatible with commercial orthopedic implants to address both septic and aseptic failures. Its outer surface features optimum bioinspired mechano-bactericidal nanostructures, capable of killing a wide spectrum of attached pathogens through a physical process to reduce the risk of bacterial infection, without directly releasing any chemicals or harming mammalian cells. On its inner surface in contact with the implant, an array of strain gauges with multiplexing transistors, built on single-crystalline silicon nanomembranes, is incorporated to map the strain experienced by the implant with high sensitivity and spatial resolution, providing information about bone-implant biomechanics for early diagnosis to minimize the probability of catastrophic instrument failures. Their multimodal functionalities, performance, biocompatibility, and stability are authenticated in sheep posterolateral fusion model and rodent implant infection model.


  • The pharmacokinetics of single oral dose extended‐release topiramate and adverse effects after multi‐dose administration in healthy cats

    by Lindsey T. Graham, Kari D. Foss, Jennifer M. Reinhart, Kathryn M. Smith, Devon W. Hague, Zhong Li

    Current treatment options for feline epilepsy are limited to medications that require administration of multiple doses per day or administration of a capsule or large tablet. Expanding the current treatment options could improve patient and owner compliance and optimize seizure control. Topiramate has been used sparingly in veterinary medicine, and limited pharmacokinetic studies have focused on immediate release formulations in dogs. If effective and safe, topiramate extended-release (XR) could broaden the current treatment options for feline epilepsy. The aims of this two-phase study were to establish single-dose pharmacokinetics for topiramate XR in cats, identify a dosing regimen that maintains steady-state plasma drug concentrations within a reference range extrapolated from human medicine (5-20 mu g/mL), and evaluate the safety of topiramate XR in cats following multidose administration. Topiramate XR administered orally at 10 mg/kg once daily for 30 days was sufficient to achieve the desired concentrations in all cats. While no clinically apparent adverse effects were observed, four out of eight cats developed subclinical anemia, calling into question the safety of topiramate XR with chronic administration. Further studies are necessary to better understand the potential adverse effects and overall efficacy of topiramate XR for the treatment of feline epilepsy.


  • Effectiveness of Supplementary Materials in Teaching the Veterinary Neurologic Examination

    by Kari D. Foss, Christopher D.A. Seals, Devon W. Hague, Ashley E. Mitek

    Clinical neurology can be difficult for veterinary students to comprehend, and part of understanding the clinical aspect is performing a proper neurologic examination. In this study, first-year veterinary students in a Small Animal Physical Exam and Anatomy rotation were given supplemental learning activities to determine their effect on student procedural knowledge and motivation in performing a neurologic examination. Students were randomly assigned to one of three groups: the first watched a video of a clinician performing the neurologic examination, the second read a handout about the neurologic exam, and the third was the control group, where students were not provided any supplemental activities. At the start and end of the rotation, students participated in a survey assessing their overall procedural knowledge and motivation to learn about the neurologic exam. No notable improvement occurred in overall student knowledge from the beginning to end of the rotation, nor when using supplemental material (p > .05). However, there was a significant difference in quiz scores between the three condition groups (p < .01), suggesting the type of learning activity did influence student learning. Additionally, students in the video and reading groups showed a significant increase in motivational scores compared with those in the control group (p < .05), demonstrating providing supplemental learning activities do improve student motivation in learning about the neurologic examination. This study provides evidence that while supplemental materials may not immediately help veterinary students learn to perform the neurologic examination, they do have a positive impact on students’ learning motivation.


  • Open Access

    Establishing an MRI-Based Protocol and Atlas of the Bearded Dragon (Pogona vitticeps) Brain

    by Kari D. Foss, Krista A. Keller, Spencer P. Kehoe, Bradley P. Sutton

    The bearded dragon (Pogona vitticeps) has become a popular companion lizard, and as such, clients have increasingly come to expect the application of advanced diagnostic and therapeutic options in their care. The purpose of this study was to establish an MRI-based protocol and brain atlas to improve diagnostic capabilities in bearded dragons presenting with neurologic dysfunction. Using a high-field 3T magnet, in vivo MRI of the brain was successfully performed in seven healthy bearded dragons utilizing an injectable anesthetic protocol utilizing intravenous alfaxalone. From this, we created an atlas of the brain in three planes, identifying nine regions of interest. A total scan time of 35 min allowed for the collection of a quality diagnostic scan and all lizards recovered without complication. This study provides practitioners a neuroanatomic reference when performing brain MRI on the bearded dragon along with a concise and rapid MRI protocol.